KEYNOTE-A18: NCT04221945: Phase 3: Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer
First Posted 2020-01-09 Trial status Active, not recruiting Sponsor Merck Sharp & Dohme LLC Abstract Presentation Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. Meeting Abstract: 2025 ASCO Annual Meeting II June 04, 2025 Click here for details LBA38 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervic
Dec 15, 2024
SU2C-SARC032: NCT03092323: Phase 2: A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity
First Posted 2017-03-27 Trial status Active, not recruiting Sponsor Sarcoma Alliance for Research through Collaboration Abstract Presentation Meeting Abstract: 2024 ASCO Annual Meeting Sarcoma - May 29, 2024 SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma. Click here for details Peer-reviewed journal publication THE LANCET Volume 404, Issue 10467p2053-2064November 23, 2024 Safety and efficacy of pembrolizuma
Dec 15, 2024